Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Radiation Oncology
Does mitochondrial myopathy increase the toxicity of breast irradiation?
Related Questions
Do you offer ultra-hypofractionated 5-fraction whole breast RT after oncoplastic rearrangement?
Is there any situation where hypofractionation of post-mastectomy radiation (CW and regional nodes) is absolutely contraindicated?
Do you offer APBI to patients with close margins?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
Would presence of DIEP flap reconstruction impact your decision to proceed with a BID approach to PMRT for inflammatory breast cancer?
How would you manage a patient with a negative axillary ultrasound but no sentinel lymph node evaluation at the time of lumpectomy for early-stage breast cancer?
Would you do APBI for encapsulated papillary carcinoma with negative margins and no surgical axillary assessment?
In a clinically node negative early stage breast cancer patient who underwent neoadjuvant systemic therapy, would surgical finding of fibrosis suspicious for treatment effect in sentinel nodes impact your RT decision?
How would you approach post-operative radiation in a patient with ER/PR negative Her2 positive, T1c N0 breast cancer originating in the ectopic mammary tissue close to the axilla, treated wide excision followed by APT regimen (weekly paclitaxel plus trastuzumab with trastuzumab for one year)?
What dose and fractionation regimen would you use for a patient with DCIS with multiple close margins unable to undergo re-excision, who has a history of photosensitivity (polymorphous light eruption)?
